Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting - Seite 2
“These data show that our novel biologic product candidate, OCU200, may offer potential benefits beyond anti-VEGF therapy and could benefit all patients who do not respond to current therapies,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. “We look forward to advancing our programs and are dedicated to making new treatment options available for patient populations affected by these diseases.”
Details for the ARVO 2021 presentation are as follows: | |
Title: | OCU200 (transferrin-tumstatin fusion protein): A potential therapeutic for DME, DR, and wet-AMD |
Presenter: | Dr. Arun Upadhyay, VP and Head of R&D, Ocugen Inc. |
Abstract No.: | 3542029 |
Session Title: | Cytokines, growth factors, anti-inflammatory |
Session Date/Time: | May 6, 2021 from 11:15 AM to 12:45 PM EDT |
URL: | https://arvo2021.arvo.org/meetings/virtual/75NdGrQYwty2WvX96 |
About Ocugen, Inc.
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing
a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic
product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are
co-developing Bharat Biotech’s COVAXIN vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.
Lesen Sie auch
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking
statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of
future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to
differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities
and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking
statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in
this press release whether as a result of new information, future events or otherwise, after the date of this press release.